Precision Advance aims to improve patient access to cell and gene therapy


October 14, 2021 -- Improving patient access to cell and gene therapy treatments is the goal of Precision Advance, an initiative of Precision Medicine Group. Precision Advance provides a set of interconnected services and personnel designed to help bring new therapies to market.

Precision Medicine Group made a major investment in Precision Advance earlier in 2021 through the acquisition of Project Farma, a bioengineering services firm that supports life sciences researchers. Project Farma specializes in planning and implementing complex biomanufacturing strategies, and has led the construction of more than a dozen manufacturing facilities.

Project Farma is now part of Precision for Medicine, Precision Medicine Group's research and development services arm, as well as Precision Advance, the company's dedicated cell and gene therapy business.

Learn more about Precision Advance, Project Farma, and Precision Medicine Group in this video.

Video loading ...


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.